KDST On Other Exchanges
Tel Aviv

kadimastem ltd (KDST) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KADIMASTEM LTD (KDST)

Related News

No related news articles were found.

kadimastem ltd (KDST) Related Businessweek News

View More BusinessWeek News

kadimastem ltd (KDST) Details

Kadimastem Ltd, a regenerative medicine company, focuses on the development and commercialization of stem cell-based therapeutics for diabetes and neurodegenerative disorders. Its products include human pluripotent stem cell-based solutions to replace the exhausting daily blood glucose monitoring and insulin injections in diabetes patients; and stem cell-based therapeutic solutions for amyotrophic lateral sclerosis, spinal cord injury, and multiple sclerosis diseases. The company was founded in 2009 and is based in Ness Ziona, Israel.

Founded in 2009

kadimastem ltd (KDST) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kadimastem ltd
Kadimastem Announces Executive Changes

Kadimastem announced recently that Yossi Ben Yosef has stepped down as Chief Executive Officer. Rami Epstein has assumed the role of Chief Executive Officer in addition to his current role as member of the Board of Directors. In order to ensure a smooth transition, Ben Yosef will continue with the company as Honorary President and strategic consultant to the Chief Executive Officer. Rami Epstein brings many years of experience as an entrepreneur mainly in the biotech, pharmaceutical and high-tech industries. His main focus is on R&D companies, fund raising, M&As and strategic collaborations. Rami is co-founder of BiondVax Pharmaceuticals and has served as a member of its Board of Directors for many years.

Kadimastem Announces the Completion of Cell Transplantation of Astrorx® in Als Patients for Cohort A in Phase I/Iia of Its Clinical Trial

Kadimastem Ltd. announced the completion of cell transplantation (AstroRx®) in 5 patients who were enrolled in Cohort A for its clinical trial in ALS. In preparation for this stage of the clinical trial the company has recently hired a production manager with many years of experience in the field of clinical production. The company has also upgraded the production system, increased its QA and production teams, and invested considerable resources in improving the production process. The phase I/IIa clinical trial is being conducted by the Department of Neurology of the Hadassah Ein-Kerem Medical Center, and it is expected to include a total of 21 patients. The objective of the trial is to evaluate the safety and efficacy of AstroRx® in patients. Results for Cohort A of the trial are expected within around half a year. The company is prepared for the next cohort of patients and is expecting to receive MOH approval by April 2019. AstroRx® contains functional healthy astrocytes (nervous system support cells) derived from human embryonic stem cells that aim to protect ALS-diseased motor neurons through several mechanisms. The company's technology enables the injection of AstroRx® cells into the patient's spinal fluid with the goal of supporting the malfunctioning cells in the brain and spinal cord, slowing the progression of the disease and improving the patient's quality of life and life expectancy.

Kadimastem Ltd, Special/Extraordinary Shareholders Meeting, Feb 05, 2019

Kadimastem Ltd, Special/Extraordinary Shareholders Meeting, Feb 05, 2019, at 16:00 Israel Standard Time. Location: The offices of Pearl Cohen Tzedek Latzer Baratz Azrieli Azrieli Tower (53th floor), 121 Menachem Begin Road Tel Aviv - Jaffa Israel


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

KDST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KDST.
View Industry Companies

Industry Analysis


Industry Average

Valuation KDST Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact KADIMASTEM LTD, please visit www.kadimastem.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.